 DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company developing novel treatments for neurological disorders and chronic kidney disease, announced today that DM199, a drug intended to restore KLK1 levels and the bodys natural ability to regulate blood flow and reduce inflammation after an acute ischemic stroke AIS, met primary safety and tolerability endpoints in the ReMEDy phase II study. Further, no DM199-related serious adverse events were noted in the study. According to top-line phase II results, there was also a demonstrated therapeutic effect in participants who received tissue plasminogen activator tPA prior to enrollment, but not in participants receiving mechanical thrombectomy. 